A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.